AOL Money & Finance

Cramer on BloggingStocks: Pelosi can't kill the health care sector

More

TheStreet.com's Jim Cramer says the Senate is filled with more-savvy politicians, and the upside for beaten-down names is huge.

Nancy Pelosi has now said her piece. The most unpopular Speaker of the House in the history of Wall Street has gotten her precious health care legislation through the House after ramming through a stimulus package that had far too little infrastructure and far too much pay raise for municipal and state workers, the most powerful interest group in the country.

But this time the Senate sees through it, and the politicians -- despite Pelosi's insistence that Tuesday's election went her way -- know better. There are pages after pages after pages in this bill that look threatening. But here's the rub: This bill's public option, the one that is supposed to be a killer to everything health care, should affect no more than 6 million people over a 10-year period, according to the Congressional Budget Office. In order to get 60 votes in the Senate, even that may prove to be too powerful an option.

Even better for the bulls, as we go into 2010 we will have seen the high-water mark of what Wall Street views as radicalism in Congress. That means you can see earnings per share increase and multiples expand for Humana (HUM) (Cramer's Take), WellPoint (WLP) (Cramer's Take), Aetna (AET) (Cramer's Take) and Cigna (CI) (Cramer's Take). You can buy Stryker (SYK) (Cramer's Take), which put up good numbers. You can expect that the highest-multiple pharma plays -- Celgene (CELG) (Cramer's Take), Abbott (ABT) (Cramer's Take) and Gilead (GILD) (Cramer's Take) -- can go higher.

You not only can stop fearing the sector, you can go overweight it -- not to mention that with Washington defanged, you can bet that the resistance upward will not be so stiff.

The House has spoken. Pelosi's spoken.

They are done talking.

The silence is golden.

Jim Cramer is co-founder and chairman of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. At the time of publication, Cramer was long Abbott and Gilead.

Reader Comments (Page 1 of 1)

Add your comments

Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.

When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.

To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br /> tags.

Symbol Lookup
IndexesChangePrice
DJIA-14.2810,318.16
NASDAQ-10.782,146.04
S&P 500-3.521,091.38

Last updated: November 20, 2009: 07:54 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines